Division of Therapeutics and Medical Consequences (DTMC)

Mission of DTMC

To use science as a vehicle for improving the treatment of Substance Use Disorders (SUDs) and their medical consequences, focusing on the identification, evaluation, and development of safe and effective therapeutics, such as medications, biologics. devices, digital, and behavioral interventions.

The DTMC achieves this mission by:

  • Supporting and conducting research on innovative pharmacological and non-pharmacological approaches for treating SUDs and facilitating recovery.
  • Collaborating with pharmaceutical companies and other federal agencies involved in therapeutic development.
  • Facilitating the regulatory approval process for new medications, devices, and digital therapeutics for SUDs.
  • Promoting the development of reliable methods to measure the safety and efficacy of SUD treatments in preclinical models and clinical trials.
  • Investigating the medical consequences of SUDs, including infections such as HIV and Hepatitis C, and developing treatments for SUDs comorbid with other health conditions.
  • Disseminating the knowledge gained from DTMC-supported research to improve the treatment outcomes of patients with SUDs.

DTMC Pipelines of Therapeutics

Opioid Use Disorder and Overdose
Opioid Use Disorder and Overdose
Early PreclinicalLate PreclinicalPhase I Clinical TrialsPhase II Clinical TrialsNew Formulation

If you have questions, please contact Ivan Montoya or Marta de Santis

Stimulant Use Disorder and Overdose
Stimulant Use Disorder and Overdose
Early PreclinicalLate PreclinicalClinical Trials
Phase IPhase IbPhase IIPhase III
 

If you have questions, please contact Katrina Foster or Ivan Montoya

Tobacco Use Disorder
Tobacco Use Disorder
Early PreclinicalLate PreclinicalClinical Trials
Phase IPhase IbPhase IIPhase III
  

If you have questions, please contact Evan Herrmann.

Cannabis Use Disorder
Cannabis Use Disorder
Early PreclinicalLate PreclinicalClinical Trials
Phase IPhase IIPhase III
 

If you have questions, please contact Aidan Hampson.

Therapeutic Devices Pipeline
Therapeutic Devices Pipeline
PreclinicalFeasibility /Target Engagement/Early EfficacyEfficacyPivotal

If you have questions, please contact Will Aklin or Jennifer Wong

Behavioral Therapies Pipeline
Behavioral Therapies Pipeline
Stage IStage IIStage III

If you have questions, please contact Will Aklin

Digital Therapeutics Pipeline
Digital Therapeutics Pipeline
Early FeasibilityFeasibilityPivotal

 

If you have questions, please contact Will Aklin

Medical Consequences Grants Portfolio
Medical Consequences Grants Portfolio
RespiratoryCardiovascularHepatitis and OtherHIV

If you have questions, please contact Will Aklin


Research Programs:

Division Listings:

Funding Opportunities

Staff Listings:

Mailing Address:

Division of Therapeutics & Medical Consequences
National Institute on Drug Abuse
C/O NIH Mail Center
3WFN MSC 6016
16071 Industrial Drive – Dock 11
Gaithersburg, MD 20892*
*(Use 20892 for U.S. Postal Service, 20877 for UPS and FedEx)

(301) 443-6173 (phone)
(301) 443-2599 (fax)